A sequential multistage-targeted nanoparticles for MR imaging and efficient chemo/chemodynamic synergistic therapy of liver cancer
Source abstract
Abstract
Abstract The reasonable combination of chemotherapy and chemodynamic therapy has great potential in the treatment of cancer. In this study, a novel multifunctional nanoparticle (CDTLG NPs) with tumor tissue-cell-mitochondria-targeted, tumor-specific drug release and endogenous reactive oxygen species generation are developed for magnetic resonance imaging-guided liver cancer synergistic chemo/chemodynamic therapy. The CDTLG NPs are constructed via self-assembled of glutathione/pH-responsive prodrug, organic chemodynamic therapy agents, and magnetic resonance imaging contrast agents. Through passive targeted, the nanosized CDTLG NPs can accumulate in tumor tissue. After accumulating in hepatoma cells by active targeting, the CDTLG NPs could be destroyed under acidic and reductive intracellular environment to quickly release chemotherapy drugs doxorubicin, camptothecin, and organic chemodynamic therapy agents. Subsequently, due to mitochondrial targeting, organic chemotherapeutic drugs accumulate in the mitochondria of hepatoma cells and generate a large number of reactive oxygen species. The burst of endogenous reactive oxygen species and chemotherapy drugs release achieved synergistic chemo/chemodynamic therapy, which led to more severe cell death than monotherapies. Furthermore, the CDTLG NPs present outstanding in vivo antitumor ability without causing obvious in vivo toxicity. Thus, the study provides an intriguing strategy to chemo/chemodynamic combination therapy-based nanoparticles for enhancing antitumor efficacy.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Cancer, Hypoxia, and Metabolism
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (39)
Show source-provided references
1. Improved antitumor activity of epirubicin-loaded CXCR4-targeted polymeric nanoparticles in liver cancers10.1016/j.ijpharm.2015.12.066 ↗
2. Enhanced delivery of doxorubicin to the liver through self-assembled nanoparticles formed via conjugation of glycyrrhetinic acid to the hydroxyl group of hyaluronic acid10.1016/j.carbpol.2018.04.052 ↗
3. Codelivery of doxorubicin and curcumin with lipid nanoparticles results in improved efficacy of chemotherapy in liver cancer
4. Reversal of multidrug resistance by stimuli-responsive drug delivery systems for therapy of tumor10.1016/j.addr.2013.04.011 ↗
5. Combination therapy: Opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines10.1016/j.addr.2009.05.006 ↗
6. Combination cancer immunotherapies tailored to the Tumour microenvironment10.1038/nrclinonc.2015.209 ↗
7. The role of iron and reactive oxygen species in cell death10.1038/nchembio.1416 ↗
8. An inorganic prodrug, tellurium nanowires with enhanced ROS generation and GSH depletion for selective cancer therapy10.1039/C9SC01070J ↗
9. Biodegradation-Mediated enzymatic Activity-Tunable molybdenum oxide nanourchins for Tumor-Specific cascade catalytic therapy10.1021/jacs.9b13586 ↗
10. Bone-targeted oxidative stress nanoamplifier for synergetic chemo/chemodynamic therapy of bone metastases through increasing generation and reducing elimination of ROS10.1016/j.cej.2020.125667 ↗
11. Photodynamic PEG-coated ROS-sensitive prodrug nanoassemblies for core-shell synergistic chemo-photodynamic therapy10.1016/j.actbio.2019.05.008 ↗
12. Micro/Nanoparticle-Augmented sonodynamic therapy (SDT): Breaking the depth shallow of photoactivation10.1002/adma.201602012 ↗
13. Ultrasound-activated sensitizers and applications10.1002/anie.201906823 ↗
14. Mitochondria-specific drug release and reactive oxygen species burst induced by polyprodrug nanoreactors can enhance chemotherapy
15. Recent advances in nanomaterial-based nanoplatforms for chemodynamic cancer therapy
16. Amorphous Fe-based nanoagents for self-enhanced chemodynamic therapy by re-establishing tumor acidosis
17. Mo2 c-derived polyoxometalate for NIR-II photoacoustic imaging-guided chemodynamic/photothermal synergistic therapy10.1002/anie.201910815 ↗
18. Mesoporous platinum nanoparticle-based nanoplatforms for combined chemo-photothermal breast cancer therapy10.1016/j.jcis.2020.02.051 ↗
19. A multistage assembly/disassembly strategy for tumor-targeted CO delivery10.1126/sciadv.aba1362 ↗
20. Platelet membrane biomimetic bufalin-loaded hollow MnO2 nanoparticles for MRI-guided chemo-chemodynamic combined therapy of cancer10.1016/j.cej.2019.122848 ↗
21. Self-assembled responsive bilayered vesicles with adjustable oxidative stress for enhanced cancer imaging and therapy10.1021/jacs.8b13902 ↗
22. Tumor-specific drug release and reactive oxygen species generation for cancer chemo/chemodynamic combination therapy
23. Macrophage membrane-coated nanocarriers Co-Modified by RVG29 and TPP improve brain neuronal mitochondria-targeting and therapeutic efficacy in Alzheimer's disease mice10.1016/j.bioactmat.2020.08.017 ↗
24. Multifunctional polymeric prodrug with simultaneous conjugating camptothecin and doxorubicin for pH/Reduction Dual-Responsive drug delivery10.1021/acsami.8b16363 ↗
25. Hierarchical targeted hepatocyte mitochondrial multifunctional chitosan nanoparticles for anticancer drug delivery10.1016/j.biomaterials.2015.02.001 ↗
26. Glycyrrhetinic acid functionalized graphene oxide for mitochondria targeting and cancer treatment in vivo
27. Glycyrrhetinic acid-decorated and reduction-sensitive micelles to enhance the bioavailability and anti-hepatocellular carcinoma efficacy of tanshinone IIA10.1039/C5BM00224A ↗
28. A positive feedback strategy for enhanced chemotherapy based on ROS-triggered self-accelerating drug release nanosystem10.1016/j.biomaterials.2017.03.010 ↗
29. Mitochondrial-Targeting Lonidamine-Doxorubicin nanoparticles for synergistic chemotherapy to conquer drug resistance10.1021/acsami.7b14577 ↗
30. Magnetic resonance Imaging-Guided Multi-Drug chemotherapy and photothermal synergistic therapy with pH and NIR-Stimulation release10.1021/acsami.7b06105 ↗
31. Redox/pH dual-stimuli responsive camptothecin prodrug nanogels for “on-demand” drug delivery10.1016/j.jconrel.2019.01.016 ↗
32. Tumor acidity activated triphenylphosphonium-based mitochondrial targeting nanocarriers for overcoming drug resistance of cancer therapy10.7150/thno.35748 ↗
33. Synergistic antitumor activity of camptothecin-doxorubicin combinations and their conjugates with hyaluronic acid10.1016/j.jconrel.2015.04.031 ↗
34. GSH/pH dual-responsive biodegradable camptothecin polymeric prodrugs combined with doxorubicin for synergistic anticancer efficiency10.1039/C9BM00425D ↗
35. In situ DOX-calcium phosphate mineralized CPT-amphiphilic gelatin nanoparticle for intracellular controlled sequential release of multiple drugs10.1016/j.actbio.2014.12.013 ↗
36. 2D germanane derivative as a vector for overcoming doxorubicin resistance in cancer cells
37. Glutathione-triggered dual release of doxorubicin and camptothecin for highly efficient synergistic anticancer therapy10.1016/j.colsurfb.2018.05.025 ↗
38. Dual-pH sensitive charge-reversal nanocomplex for tumor-targeted drug delivery with enhanced anticancer activity10.7150/thno.18607 ↗
39. Preparation and characterization of DOX loaded keratin nanoparticles for pH/GSH dual responsive release10.1016/j.msec.2016.12.067 ↗